Determination That ACTHAR GEL SYNTHETIC (Seractide Acetate) Injection, 80 Units/Milliliter and 40 Units/Milliliter, Was Withdrawn From Sale for Reasons of Safety or Effectiveness, 7837-7839 [2017-01249]
Download as PDF
7837
Federal Register / Vol. 82, No. 13 / Monday, January 23, 2017 / Notices
• Ensure adequate and timely
reporting of program data to relevant
federal agencies and stakeholders
including the Congress, and members of
the public.
Tribal HV Form 2 will provide a
template for Tribal MIECHV grantees to
report data on their progress under the
six benchmark areas as stipulated in
legislation.
Respondents: Tribal Maternal, Infant,
and Early Childhood Home Visiting
Program Grantees.
ANNUAL BURDEN ESTIMATES
Instrument
Number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
Tribal Maternal, Infant, and Early Childhood Home Visiting Performance Reporting Form .................................................................................................
20
1
500
10,000
Estimated Total Annual Burden
Hours: 10,000.
In compliance with the requirements
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 330 C St. SW.,
Washington, DC 20201, Attn: OPRE
Reports Clearance Officer. Email
address: OPREinfocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.
The Department specifically requests
comments on: (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
mstockstill on DSK3G9T082PROD with NOTICES
Mary Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2017–01276 Filed 1–19–17; 8:45 am]
BILLING CODE 4184–01–P
VerDate Sep<11>2014
19:02 Jan 19, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–P–0377]
Determination That ACTHAR GEL
SYNTHETIC (Seractide Acetate)
Injection, 80 Units/Milliliter and 40
Units/Milliliter, Was Withdrawn From
Sale for Reasons of Safety or
Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or we) has
determined that ACTHAR GEL
SYNTHETIC (seractide acetate)
injection, 80 units/milliliter (mL) and 40
units/mL, was withdrawn from sale for
reasons of safety or effectiveness. The
Agency will not accept or approve
abbreviated new drug applications
(ANDAs) for seractide acetate injection,
80 units/mL and 40 units/mL.
FOR FURTHER INFORMATION CONTACT:
David E. Markert, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6222,
Silver Spring, MD 20993–0002, 301–
796–0752.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
In 1984, Congress enacted the Drug
Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
(the 1984 amendments), which
authorized the approval of duplicate
versions of drug products under an
ANDA procedure. ANDA applicants
must, with certain exceptions, show that
the drug for which they are seeking
approval contains the same active
ingredient in the same strength and
dosage form as the ‘‘listed drug,’’ which
is a version of the drug that was
previously approved. ANDA applicants
do not have to repeat the extensive
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
clinical testing otherwise necessary to
gain approval of a new drug application
(NDA).
The 1984 amendments include what
is now section 505(j)(7) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
355(j)(7)), which requires FDA to
publish a list of all approved drugs.
FDA publishes this list as part of the
‘‘Approved Drug Products With
Therapeutic Equivalence Evaluations,’’
which is known generally as the
‘‘Orange Book.’’ Under FDA regulations,
drugs are removed from the list if the
Agency withdraws or suspends
approval of the drug’s NDA or ANDA
for reasons of safety or effectiveness or
if FDA determines that the listed drug
was withdrawn from sale for reasons of
safety or effectiveness (21 CFR 314.162).
A person may petition the Agency to
determine, or the Agency may
determine on its own initiative, whether
a listed drug was withdrawn from sale
for reasons of safety or effectiveness.
This determination may be made at any
time after the drug has been withdrawn
from sale, but must be made prior to
approving an ANDA that refers to the
listed drug (21 CFR 314.161). FDA may
not approve an ANDA that does not
refer to a listed drug.
ACTHAR GEL SYNTHETIC (seractide
acetate) injection, 80 units/mL and 40
units/mL was the subject of NDA
017861, which was held by Armour
Pharmaceutical Co. (Armour), and
initially approved on February 21, 1978.
ACTHAR GEL SYNTHETIC is indicated
for diagnostic testing of adrenocortical
function. The labeling also provides that
ACTHAR GEL SYNTHETIC may be
employed in the following disorders:
Endocrine Disorders: Nonsuppurative
thyroiditis; Hypercalcemia associated
with cancer.
Nervous System Diseases: Acute
exacerbations of multiple sclerosis.
Rheumatic Disorders: As adjunctive
therapy for short-term administration (to
tide the patient over an acute episode or
exacerbation) in: Psoriatic arthritis;
rheumatoid arthritis, including juvenile
E:\FR\FM\23JAN1.SGM
23JAN1
mstockstill on DSK3G9T082PROD with NOTICES
7838
Federal Register / Vol. 82, No. 13 / Monday, January 23, 2017 / Notices
rheumatoid arthritis (selected cases may
require low-dose maintenance therapy);
ankylosing spondylitis; acute and
subacute bursitis; acute non-specific
tenosynovitis; acute gouty arthritis;
post-traumatic arthritis; synovitis of
osteoarthritis; epicondylitis.
Collagen Diseases: During an
exacerbation or as maintenance therapy
in selected cases of: Systemic lupus
erythematosus; systemic
dermatomyositis (polymyositis); acute
rheumatic carditis.
Dermatologic Diseases: Pemphigus;
bullous dermatitis herpetiformis; severe
erythema multiforme (Stevens-Johnson
syndrome); exfoliative dermatitis; severe
psoriasis; severe seborrheic dermatitis;
mycosis fungoides.
Allergic States: Control of severe or
incapacitating allergic conditions
intractable to adequate trials of
conventional treatment—seasonal or
perennial allergic rhinitis; bronchial
asthma; contact dermatitis; atopic
dermatitis; serum sickness.
Ophthalmic Diseases: Severe acute
and chronic allergic and inflammatory
processes involving the eye and its
adnexa such as: Allergic conjunctivitis;
keratitis; herpes zoster ophthalmicus;
iritis and iridocyclitis; diffuse posterior
uveitis and choroiditis; optic neuritis;
sympathetic ophthalmia; chorioretinitis;
anterior segment inflammation; allergic
corneal marginal ulcers.
Respiratory Diseases: Symptomatic
sarcoidosis; Loeffler’s syndrome not
manageable by other means; berylliosis;
fulminating or disseminated pulmonary
tuberculosis when used concurrently
with anti-tuberculous chemotherapy;
aspiration pneumonitis.
Hematologic Disorders: Acquired
(autoimmune) hemolytic anemia;
secondary thrombocytopenia in adults;
erythroblastopenia (RBC anemia);
congenital (erythroid) hypoplastic
anemia.
Neoplastic Diseases: For palliative
management of: Leukemias and
lymphomas in adults; acute leukemia of
childhood.
Edematous State: To induce a diuresis
or a remission of proteinuria in the
nephrotic syndrome without uremia of
the idiopathic type or that due to lupus
erythematosus.
Gastrointestinal Diseases: To tide the
patient over a critical period of the
disease in: Ulcerative colitis; regional
enteritis.
Miscellaneous: Tuberculous
meningitis with subarachnoid block or
impending block when concurrently
accompanied by appropriate antituberculous chemotherapy; trichinosis
with neurologic or myocardial
involvement.
VerDate Sep<11>2014
19:02 Jan 19, 2017
Jkt 241001
Armour never marketed ACTHAR
GEL SYNTHETIC (seractide acetate)
injection, 80 units/mL and 40 units/mL.
In previous instances (see, e.g., 72 FR
9763, March 5, 2007 and 61 FR 25497,
May 21, 1996), the Agency has
determined that for purposes of
§§ 314.161 and 314.162, never
marketing an approved drug product is
equivalent to withdrawing the drug
from sale. FDA withdrew approval of
the NDA for ACTHAR GEL SYNTHETIC
in 2014 because Armour had repeatedly
failed to file annual reports for the
application (79 FR 68454, November 17,
2014).
Hyman, Phelps & McNamara, P.C.,
submitted a citizen petition dated April
1, 2014 (Docket No. FDA–2014–P–
0377), under 21 CFR 10.30, requesting
that the Agency determine whether
ACTHAR GEL SYNTHETIC (seractide
acetate) injection, 80 units/mL and 40
units/mL, was withdrawn from sale for
reasons of safety or effectiveness.
II. Response to Citizen Petition
We have carefully reviewed the
citizen petition (and comments
submitted to the docket); our records for
ACTHAR GEL SYNTHETIC (seractide
acetate) injection, 80 units/mL and 40
units/mL; the scientific literature on
seractide acetate; and other relevant
information. Based on that review, and
for the reasons set forth in this section,
we have concluded that additional
studies of safety would be necessary
before ACTHAR GEL SYNTHETIC could
be considered for introduction to the
market today. Consequently, FDA has
determined under § 314.161 that
ACTHAR GEL SYNTHETIC (seractide
acetate) injection, 80 units/mL and 40
units/mL, was withdrawn for reasons of
safety.1
The labeling for ACTHAR GEL
SYNTHETIC describes the product as ‘‘a
highly purified synthetic polypeptide
containing thirty-nine amino acids in
the sequence described for human
corticotropin by Lee, T.H.; Lerner, A.B.;
and Buettner-Janusch, Vina (J. Biol
Chem, 236:2970–2974, Nov. 1961)’’
(Refs. 1 and 2). At the time of ACTHAR
GEL SYNTHETIC’s approval, FDA
believed the amino acid sequence
described by Lee et al. was the correct
sequence for human corticotropin and,
therefore, that ACTHAR GEL
SYNTHETIC was identical to human
1 In light of this conclusion, it is unnecessary for
us to determine whether ACTHAR GEL
SYNTHETIC was also withdrawn from sale for
reasons of effectiveness. This notice does not
address the effectiveness of ACTHAR GEL
SYNTHETIC for its labeled indications.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
corticotropin.2 However, since approval,
the Agency has learned that ACTHAR
GEL SYNTHETIC is not identical to the
human corticotropin sequence. We now
know that the amino acid sequence
described by Lee et al. is a deamidated
version of human corticotropin that
differs from full length human
corticotropin at four positions.3
The fact that ACTHAR GEL
SYNTHETIC has a different amino acid
sequence from human corticotropin
raises significant safety concerns. Due to
its different amino acid sequence,
ACTHAR GEL SYNTHETIC might have
a structure or function that is not
recognized as endogenous by the
immune system. ACTHAR GEL
SYNTHETIC thus poses a higher risk of
immunogenicity than a synthetic
peptide product that is, in fact, identical
to human corticotropin. The health
consequences of immunogenicity range
from subacute, minor reactions to
severe, even deadly, reactions (e.g.,
anaphylaxis). In addition, frequent
stimulation of the immune system could
produce antibodies that cross-react with
human corticotropin and other closely
related endogenous peptides, resulting
in the loss of those peptides’
physiological functions. Such an effect
could last long after treatment with
ACTHAR GEL SYNTHETIC has
stopped.
The safety concerns noted in this
section have not been adequately
investigated. ACTHAR GEL
SYNTHETIC was studied in two clinical
trials in 51 healthy adult men between
21 and 54 years old. Although no
unusual adverse effects were reported
during these trials, the trials did not
assess the impact of immunogenicity on
safety. Nor were they designed to assess
immunogenicity. Moreover, because
ACTHAR GEL SYNTHETIC was never
marketed, the Agency has no
postmarketing safety data or information
confirming that the product is safe for
human use, notwithstanding the
differences between ACTHAR GEL
SYNTHETIC’s amino acid sequence and
that of human corticotropin. Given the
lack of any premarket or postmarket
2 The Agency’s Institutional Summary of Basis of
Approval (Ref. 3) describes ACTHAR GEL
SYNTHETIC as ‘‘a synthetic peptide of 39 amino
acids identical with that of natural human’’
corticotropin.
3 The record for human pro-opiomelanocortin
preproprotein in the National Center for
Biotechnology Information’s ‘‘Protein’’ database
(Reference Sequence NP_000930.1) contains the
correct amino acid sequence for human
corticotropin. The record is available at the
following URL: https://www.ncbi.nlm.nih.gov/
protein/NP_000930.1. The sequence described by
Lee et al. differs from the correct sequence at
positions 25–27 and 30.
E:\FR\FM\23JAN1.SGM
23JAN1
Federal Register / Vol. 82, No. 13 / Monday, January 23, 2017 / Notices
immunogenicity safety data, FDA
cannot conclude that ACTHAR GEL
SYNTHETIC would be safe for human
use if it were introduced to the market
today.
Accordingly, the Agency will remove
ACTHAR GEL SYNTHETIC (seractide
acetate) injection, 80 units/mL and 40
units/mL, from the list of drug products
published in the Orange Book. FDA will
not accept or approve ANDAs that refer
to this drug product.
III. References
The following references have been
placed on display in the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852,
and are available for viewing by
interested persons between 9 a.m. and 4
p.m., Monday through Friday; they are
also available electronically at https://
www.regulations.gov.
1. Armour Pharmaceutical Co., ‘‘ACTHAR®
Gel Synthetic (SERACTIDE ACETATE),
Synthetic Corticotropin,’’ Product
Labeling, 1979.
2. Lee, T. H., A. B. Lerner, and V. BuettnerJanusch, ‘‘On the Structure of Human
Corticotropin (Adrenocorticotropic
Hormone),’’ The Journal of Biological
Chemistry, vol. 236, pp. 2970–2974,
1961.
3. FDA, ‘‘Seractide Acetate: Institutional
Summary of Basis of Approval,’’ August
22, 1977.
Dated: January 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017–01249 Filed 1–19–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0825]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Premarket
Approval of Medical Devices
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by February
22, 2017.
mstockstill on DSK3G9T082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:02 Jan 19, 2017
Jkt 241001
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0231. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, Three White
Flint North 10A63, 11601 Landsdown
St., North Bethesda, MD 20852,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
ADDRESSES:
Premarket Approval of Medical
Devices—OMB Control Number 0910–
0231—Extension
Under section 515 of the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 360e) all devices
placed into class III by FDA are subject
to premarket approval (PMA)
requirements. PMA is the process of
scientific and regulatory review to
ensure the safety and effectiveness of
class III devices. An approved PMA is,
in effect, a private license granted to the
applicant for marketing a particular
medical device. A class III device that
fails to meet PMA requirements is
considered to be adulterated under
section 501(f) of the FD&C Act (21
U.S.C. 351(f)) and cannot be marketed.
PMA requirements apply differently to
preamendments devices,
postamendments devices, and
transitional class III devices.
Manufacturers of class III
preamendments devices, devices that
were in commercial distribution before
May 28, 1976, are not required to submit
a PMA until 30 months after the
issuance of a final classification
regulation or until 90 days after the
publication of a final regulation
requiring the submission of a PMA,
whichever period is later. FDA may
allow more than 90 days after issuance
of a final rule for submission of a PMA.
A postamendments device is one that
was first distributed commercially on or
after May 28, 1976. Postamendments
devices determined by FDA to be
substantially equivalent to
preamendments class III devices are
subject to the same requirements as the
preamendments devices. FDA
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
7839
determines substantial equivalence after
reviewing an applicant’s premarket
notification submitted in accordance
with section 510(k) of the FD&C Act (21
U.S.C. 360(k)). Postamendments devices
determined by FDA to be not
substantially equivalent to either
preamendments devices or
postamendments devices classified into
class I or II are ‘‘new’’ devices and fall
automatically into class III. Before such
devices can be marketed, they must
have an approved PMA application or
be must reclassified into class I or class
II.
The Food and Drug Modernization
Act of 1997 (FDAMA) (Pub. L. 105–115)
was enacted on November 21, 1997, to
implement revisions to the FD&C Act by
streamlining the process of bringing safe
and effective drugs, medical devices,
and other therapies to the U.S. market.
FDAMA added section 515(d)(6) to the
FD&C Act (21 U.S.C. 360e(d)(6)), which
provided that PMA supplements were
required for all device changes that
affect safety and effectiveness unless
such changes are modifications to
manufacturing procedures or method of
manufacture. That type of
manufacturing change will require a 30day notice, or where FDA finds such
notice inadequate, a 135-day PMA
supplement.
The implementing regulations,
contained in part 814 (21 CFR part 814),
further specify the contents of a PMA
for a medical device and the criteria
FDA will employ in approving, denying,
or withdrawing approval of a PMA and
supplements to PMAs. The regulations’
purpose is to establish an efficient and
thorough procedure for FDA’s review of
PMAs and supplements to PMAs for
class III medical devices. The
regulations facilitate the approval of
PMAs and supplements to PMAs for
devices that have been shown to be
reasonably safe and effective and
otherwise meet the statutory criteria for
approval. The regulations also ensure
the denial of PMAs and supplements to
PMAs for devices that have not been
shown to be reasonably safe and
effective and that do not otherwise meet
the statutory criteria for approval.
The industry-wide burden estimate
for PMAs is based on an FDA average
fiscal year (FY) annual rate of receipt of
PMA submissions data FYs 2013
through 2015 and our expectation of
submissions to come in the next few
years. The burden data for PMAs is
based on data provided by applicants by
device type and cost element in an
earlier study.
Reporting Burden: The reporting
burden can be broken out by certain
E:\FR\FM\23JAN1.SGM
23JAN1
Agencies
[Federal Register Volume 82, Number 13 (Monday, January 23, 2017)]
[Notices]
[Pages 7837-7839]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-01249]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-P-0377]
Determination That ACTHAR GEL SYNTHETIC (Seractide Acetate)
Injection, 80 Units/Milliliter and 40 Units/Milliliter, Was Withdrawn
From Sale for Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) has determined
that ACTHAR GEL SYNTHETIC (seractide acetate) injection, 80 units/
milliliter (mL) and 40 units/mL, was withdrawn from sale for reasons of
safety or effectiveness. The Agency will not accept or approve
abbreviated new drug applications (ANDAs) for seractide acetate
injection, 80 units/mL and 40 units/mL.
FOR FURTHER INFORMATION CONTACT: David E. Markert, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6222, Silver Spring, MD 20993-0002, 301-
796-0752.
SUPPLEMENTARY INFORMATION:
I. Background
In 1984, Congress enacted the Drug Price Competition and Patent
Term Restoration Act of 1984 (Pub. L. 98-417) (the 1984 amendments),
which authorized the approval of duplicate versions of drug products
under an ANDA procedure. ANDA applicants must, with certain exceptions,
show that the drug for which they are seeking approval contains the
same active ingredient in the same strength and dosage form as the
``listed drug,'' which is a version of the drug that was previously
approved. ANDA applicants do not have to repeat the extensive clinical
testing otherwise necessary to gain approval of a new drug application
(NDA).
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness (21
CFR 314.162).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale,
but must be made prior to approving an ANDA that refers to the listed
drug (21 CFR 314.161). FDA may not approve an ANDA that does not refer
to a listed drug.
ACTHAR GEL SYNTHETIC (seractide acetate) injection, 80 units/mL and
40 units/mL was the subject of NDA 017861, which was held by Armour
Pharmaceutical Co. (Armour), and initially approved on February 21,
1978. ACTHAR GEL SYNTHETIC is indicated for diagnostic testing of
adrenocortical function. The labeling also provides that ACTHAR GEL
SYNTHETIC may be employed in the following disorders:
Endocrine Disorders: Nonsuppurative thyroiditis; Hypercalcemia
associated with cancer.
Nervous System Diseases: Acute exacerbations of multiple sclerosis.
Rheumatic Disorders: As adjunctive therapy for short-term
administration (to tide the patient over an acute episode or
exacerbation) in: Psoriatic arthritis; rheumatoid arthritis, including
juvenile
[[Page 7838]]
rheumatoid arthritis (selected cases may require low-dose maintenance
therapy); ankylosing spondylitis; acute and subacute bursitis; acute
non-specific tenosynovitis; acute gouty arthritis; post-traumatic
arthritis; synovitis of osteoarthritis; epicondylitis.
Collagen Diseases: During an exacerbation or as maintenance therapy
in selected cases of: Systemic lupus erythematosus; systemic
dermatomyositis (polymyositis); acute rheumatic carditis.
Dermatologic Diseases: Pemphigus; bullous dermatitis herpetiformis;
severe erythema multiforme (Stevens-Johnson syndrome); exfoliative
dermatitis; severe psoriasis; severe seborrheic dermatitis; mycosis
fungoides.
Allergic States: Control of severe or incapacitating allergic
conditions intractable to adequate trials of conventional treatment--
seasonal or perennial allergic rhinitis; bronchial asthma; contact
dermatitis; atopic dermatitis; serum sickness.
Ophthalmic Diseases: Severe acute and chronic allergic and
inflammatory processes involving the eye and its adnexa such as:
Allergic conjunctivitis; keratitis; herpes zoster ophthalmicus; iritis
and iridocyclitis; diffuse posterior uveitis and choroiditis; optic
neuritis; sympathetic ophthalmia; chorioretinitis; anterior segment
inflammation; allergic corneal marginal ulcers.
Respiratory Diseases: Symptomatic sarcoidosis; Loeffler's syndrome
not manageable by other means; berylliosis; fulminating or disseminated
pulmonary tuberculosis when used concurrently with anti-tuberculous
chemotherapy; aspiration pneumonitis.
Hematologic Disorders: Acquired (autoimmune) hemolytic anemia;
secondary thrombocytopenia in adults; erythroblastopenia (RBC anemia);
congenital (erythroid) hypoplastic anemia.
Neoplastic Diseases: For palliative management of: Leukemias and
lymphomas in adults; acute leukemia of childhood.
Edematous State: To induce a diuresis or a remission of proteinuria
in the nephrotic syndrome without uremia of the idiopathic type or that
due to lupus erythematosus.
Gastrointestinal Diseases: To tide the patient over a critical
period of the disease in: Ulcerative colitis; regional enteritis.
Miscellaneous: Tuberculous meningitis with subarachnoid block or
impending block when concurrently accompanied by appropriate anti-
tuberculous chemotherapy; trichinosis with neurologic or myocardial
involvement.
Armour never marketed ACTHAR GEL SYNTHETIC (seractide acetate)
injection, 80 units/mL and 40 units/mL. In previous instances (see,
e.g., 72 FR 9763, March 5, 2007 and 61 FR 25497, May 21, 1996), the
Agency has determined that for purposes of Sec. Sec. 314.161 and
314.162, never marketing an approved drug product is equivalent to
withdrawing the drug from sale. FDA withdrew approval of the NDA for
ACTHAR GEL SYNTHETIC in 2014 because Armour had repeatedly failed to
file annual reports for the application (79 FR 68454, November 17,
2014).
Hyman, Phelps & McNamara, P.C., submitted a citizen petition dated
April 1, 2014 (Docket No. FDA-2014-P-0377), under 21 CFR 10.30,
requesting that the Agency determine whether ACTHAR GEL SYNTHETIC
(seractide acetate) injection, 80 units/mL and 40 units/mL, was
withdrawn from sale for reasons of safety or effectiveness.
II. Response to Citizen Petition
We have carefully reviewed the citizen petition (and comments
submitted to the docket); our records for ACTHAR GEL SYNTHETIC
(seractide acetate) injection, 80 units/mL and 40 units/mL; the
scientific literature on seractide acetate; and other relevant
information. Based on that review, and for the reasons set forth in
this section, we have concluded that additional studies of safety would
be necessary before ACTHAR GEL SYNTHETIC could be considered for
introduction to the market today. Consequently, FDA has determined
under Sec. 314.161 that ACTHAR GEL SYNTHETIC (seractide acetate)
injection, 80 units/mL and 40 units/mL, was withdrawn for reasons of
safety.\1\
---------------------------------------------------------------------------
\1\ In light of this conclusion, it is unnecessary for us to
determine whether ACTHAR GEL SYNTHETIC was also withdrawn from sale
for reasons of effectiveness. This notice does not address the
effectiveness of ACTHAR GEL SYNTHETIC for its labeled indications.
---------------------------------------------------------------------------
The labeling for ACTHAR GEL SYNTHETIC describes the product as ``a
highly purified synthetic polypeptide containing thirty-nine amino
acids in the sequence described for human corticotropin by Lee, T.H.;
Lerner, A.B.; and Buettner-Janusch, Vina (J. Biol Chem, 236:2970-2974,
Nov. 1961)'' (Refs. 1 and 2). At the time of ACTHAR GEL SYNTHETIC's
approval, FDA believed the amino acid sequence described by Lee et al.
was the correct sequence for human corticotropin and, therefore, that
ACTHAR GEL SYNTHETIC was identical to human corticotropin.\2\ However,
since approval, the Agency has learned that ACTHAR GEL SYNTHETIC is not
identical to the human corticotropin sequence. We now know that the
amino acid sequence described by Lee et al. is a deamidated version of
human corticotropin that differs from full length human corticotropin
at four positions.\3\
---------------------------------------------------------------------------
\2\ The Agency's Institutional Summary of Basis of Approval
(Ref. 3) describes ACTHAR GEL SYNTHETIC as ``a synthetic peptide of
39 amino acids identical with that of natural human'' corticotropin.
\3\ The record for human pro-opiomelanocortin preproprotein in
the National Center for Biotechnology Information's ``Protein''
database (Reference Sequence NP_000930.1) contains the correct amino
acid sequence for human corticotropin. The record is available at
the following URL: https://www.ncbi.nlm.nih.gov/protein/NP_000930.1.
The sequence described by Lee et al. differs from the correct
sequence at positions 25-27 and 30.
---------------------------------------------------------------------------
The fact that ACTHAR GEL SYNTHETIC has a different amino acid
sequence from human corticotropin raises significant safety concerns.
Due to its different amino acid sequence, ACTHAR GEL SYNTHETIC might
have a structure or function that is not recognized as endogenous by
the immune system. ACTHAR GEL SYNTHETIC thus poses a higher risk of
immunogenicity than a synthetic peptide product that is, in fact,
identical to human corticotropin. The health consequences of
immunogenicity range from subacute, minor reactions to severe, even
deadly, reactions (e.g., anaphylaxis). In addition, frequent
stimulation of the immune system could produce antibodies that cross-
react with human corticotropin and other closely related endogenous
peptides, resulting in the loss of those peptides' physiological
functions. Such an effect could last long after treatment with ACTHAR
GEL SYNTHETIC has stopped.
The safety concerns noted in this section have not been adequately
investigated. ACTHAR GEL SYNTHETIC was studied in two clinical trials
in 51 healthy adult men between 21 and 54 years old. Although no
unusual adverse effects were reported during these trials, the trials
did not assess the impact of immunogenicity on safety. Nor were they
designed to assess immunogenicity. Moreover, because ACTHAR GEL
SYNTHETIC was never marketed, the Agency has no postmarketing safety
data or information confirming that the product is safe for human use,
notwithstanding the differences between ACTHAR GEL SYNTHETIC's amino
acid sequence and that of human corticotropin. Given the lack of any
premarket or postmarket
[[Page 7839]]
immunogenicity safety data, FDA cannot conclude that ACTHAR GEL
SYNTHETIC would be safe for human use if it were introduced to the
market today.
Accordingly, the Agency will remove ACTHAR GEL SYNTHETIC (seractide
acetate) injection, 80 units/mL and 40 units/mL, from the list of drug
products published in the Orange Book. FDA will not accept or approve
ANDAs that refer to this drug product.
III. References
The following references have been placed on display in the
Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, and are available for
viewing by interested persons between 9 a.m. and 4 p.m., Monday through
Friday; they are also available electronically at https://www.regulations.gov.
1. Armour Pharmaceutical Co., ``ACTHAR[supreg] Gel Synthetic
(SERACTIDE ACETATE), Synthetic Corticotropin,'' Product Labeling,
1979.
2. Lee, T. H., A. B. Lerner, and V. Buettner-Janusch, ``On the
Structure of Human Corticotropin (Adrenocorticotropic Hormone),''
The Journal of Biological Chemistry, vol. 236, pp. 2970-2974, 1961.
3. FDA, ``Seractide Acetate: Institutional Summary of Basis of
Approval,'' August 22, 1977.
Dated: January 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-01249 Filed 1-19-17; 8:45 am]
BILLING CODE 4164-01-P